Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Status:
Terminated
Trial end date:
2018-07-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering
effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to
Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular
hypertension.